Key facts
- XyloCor Therapeutics’s last known valuation is $130.0M (Jan 2025).
- It has raised $122.0M across 3 recorded rounds; the latest was Seed Round ($4.0M) in Jan 2021.
- Notable investors include EQT Life Sciences, Cornell University, Fountain Healthcare Partners, Jeito, Longwood Fund — 8 tracked in total.
- XyloCor Therapeutics has filed 6 Form Ds with the SEC since 2016, most recently Jan 2021 ($4.0M sold to 5 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for XyloCor Therapeutics
Funding rounds
3 roundsAbout XyloCor Therapeutics
Operator of a bio-pharmaceutical firm intended to develop gene therapy for people with advanced coronary artery disease. The company's firm focuses on developing gene therapy to stimulate the formation of new coronary blood vessels and serve areas of the heart that are not receiving adequate blood supply, enabling patients with refractory angina who exhausted pharmacologic options to cure their cardiovascular diseases painlessly and cost-effectively.
- Sector
- Healthcare
- HQ
- King of Prussia, PA, United States
- Founded
- 2013
- Employees
- 16
- Website
- xylocor.com/
- Ownership
- Privately Held (backing)
XyloCor Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in XyloCor Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on XyloCor Therapeutics in its N-PORT filings yet. We sweep new filings monthly.